TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT04655339
Drug: Bilateral abdominal Lap-TAP
Approvals — FDA: no, EMA: no, PMDA: no
Description: A total of 30ml of anesthetic (0.25% Bupivacaine HCL), 0.25% Liposomal Bupivacaine (Exparel®) or control will be injected into the transversus abdominis plane bilaterally. A long spinal needle attached to a 30cc syringe with the TAP block solution or control will be used to inject the patient. The needle puncture will be halfway between the subcostal margin and anterior superior iliac spine at the midclavicular line. With laparoscopic guidance, needle will enter through the skin, external oblique and internal oblique. Once the needle is in place, injection of 30 ml on each side will be applied between the internal oblique and transversus abdominis muscle. The injection of bupivacaine into this abdominal wall induces an observable bulge, indicating accuracy of the procedure. These steps will be repeated on the contralateral side of the abdomen. All patients will receive 10 ml bupivacaine 0.25% pre-incision infiltration.
Study: NCT01887366
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subjects assigned to placebo will be administered one intra-muscular (IM) injection once weekly over 12 weeks. Subjects in this treatment group will receive 3.0 mL placebo.
Study: NCT00727441
Drug: cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Given IV (Arm B), given orally (Arm C)
Study: NCT00216073
Drug: Capecitabine
Normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Capecitabine 825 mg/m2 po bid, days 1-14
Study: NCT00642889
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01015456
Drug: cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: intravenous, monthly, for 6 months
Study: NCT02617485
Drug: Doxorubicin
Normalized name: Doxorubicin
DrugBank: Doxorubicin (DB00997)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 50 mg of doxorubicin per square meter administrated IV on day 1 of each chemotherapy cycle
Study: NCT02617485
Drug: Cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 750 mg of cyclophosphamide per square meter of body-surface area administrated IV on day 1 of each chemotherapy cycle
Study: NCT00395057
Drug: AGN 211745
Normalized name: VITEX AGNUS-CASTUS WHOLE
Approvals — FDA: no, EMA: no, PMDA: no
Description: AGN 211745 Solution 1000µg injection at Day 1, Month 1, Month 2
Study: NCT00395057
Drug: AGN 211745
Normalized name: VITEX AGNUS-CASTUS WHOLE
Approvals — FDA: no, EMA: no, PMDA: no
Description: AGN 211745 Solution 300µg injections, Day 1, Month 1, Month 2
Study: NCT00395057
Drug: AGN 211745
Normalized name: VITEX AGNUS-CASTUS WHOLE
Approvals — FDA: no, EMA: no, PMDA: no
Description: AGN 211745 Solution 100µg injections, Day 1, Month 1, Month 2
Study: NCT04917302
Drug: NMDAE plus AIFA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Use of an NMDA enhancer plus a drug with anti-inflammatory property for the treatment of schizophrenia.
Study: NCT04917302
Drug: NMDAE plus Placebo Cap
Approvals — FDA: no, EMA: no, PMDA: no
Description: Use of an NMDA enhancer plus placebo as a comparator
Study: NCT04545541
Drug: Nebulised unfractionated heparin (UFH)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nebulised UFH (25,000 Units in 5 mL) will be administered 6-hourly via an Aerogen Solo vibrating mesh nebuliser while patients receive invasive mechanical ventilation in ICU and for a maximum of 10 days.
Study: NCT03020303
Drug: Spironolactone 25Mg Tablet
Normalized name: Spironolactone
DrugBank: Spironolactone (DB00421)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Randomized participants will receive a study supply of spironolactone 25 mg tablets. They will be instructed to take 1 tablet daily.
Study: NCT01109056
Drug: Vehicle
Normalized name: Drug vehicle
Approvals — FDA: no, EMA: no, PMDA: no
Description: One drop in the study eye (or eyes) administered four times daily (QID)
Study: NCT03486327
Drug: BR55
Normalized name: Band-Aid Ourtone BR55 Bandages
Approvals — FDA: no, EMA: no, PMDA: no
Description: A novel targeted ultrasound contrast agent
Study: NCT03347929
Drug: Naproxen 500 Mg
Normalized name: naproxen 500 MG
DrugBank: Naproxen (DB00788)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 10 days treatment with Naproxen 500 mg twice daily
Study: NCT03347929
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 days treatment with Placebo1 tablet twice daily
Study: NCT02856282
Drug: Pirinase Hayfever Relief for Adults 0.05% Nasal Spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aqueous suspension of 0.05% micronised fluticasone propionate.Each actuation contains 50 micrograms of fluticasone propionate
Study: NCT02074982
Drug: AIN457 300 mg
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT03020303
Drug: Placebo Oral Tablet
Normalized name: placebo ORAL TABLET
Approvals — FDA: no, EMA: no, PMDA: no
Description: Randomized participants will receive a study supply of placebo tablets with no active medical ingredients. They will be instructed to take 1 tablet daily.
Study: NCT02845219
Drug: SNAC
Normalized name: Glucerna Snack Bar
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral administration once daily together with oral contraceptive.
Study: NCT02845219
Drug: Microgynon®
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral administration once daily alone or together with oral semaglutide or SNAC.
Study: NCT02248428
Drug: Clarithromycin
Normalized name: Clarithromycin
DrugBank: Clarithromycin (DB01211)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 500mg orally daily on days 1-28,repeated every 28 days
Study: NCT02248428
Drug: Cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 300mg/m\^2 intravenously daily on day 1-3,repeated every 28 days
Study: NCT03940183
Drug: Placebo Oral Tablet
Normalized name: placebo ORAL TABLET
Approvals — FDA: no, EMA: no, PMDA: no
Description: the placebo Comparator groups use placebo oral tablet for 24weeks
Study: NCT03565367
Drug: Hyperpolarized Carbon C 13 Pyruvate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Given IV
Study: NCT03005873
Drug: TLC599 LD group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single dose via intra-articular injection
Study: NCT03005873
Drug: Normal Saline
Normalized name: Normal Saline Flush
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single dose via intra-articular injection
Study: NCT03005873
Drug: TLC599 HD group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single dose via intra-articular injection
Study: NCT00532675
Drug: LBH589
Approvals — FDA: no, EMA: no, PMDA: no
Description: PAN 5 mg and PAN 20 mg capsules
Study: NCT04585009
Drug: GSK3923868
Approvals — FDA: no, EMA: no, PMDA: no
Description: GSK3923868 will be available as capsules containing inhalation powder blend to be delivered via Monodose RS01 device.
Study: NCT04585009
Drug: Matching placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo to match GSK3923868 will be available as capsule containing inhalation powder to be delivered via Monodose RS01 device.
Study: NCT02416167
Drug: FYU-981
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02416167
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01473589
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered by SC injection
Study: NCT03560518
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (prefilled syringe, weekly IV administration)
Study: NCT03140527
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo
Study: NCT01128621
Drug: GSK1292263
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tablet
Study: NCT01128621
Drug: GSK1292263 matching placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tablet
Study: NCT02685059
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo i.v. every 4 weeks~As monotherapy for the first two weeks (0.75g absolute) (part 1) followed by:~Placebo in combination with nab-paclitaxel 125 mg/m² every week for 12 weeks (part 2) followed by~MEDI4736/Placebo in combination with epirubicin 90mg/m² plus cyclophosphamide 600 mg/m² every 2 weeks for 4 cycles (part 3).
Study: NCT02685059
Drug: Cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Cyclophosphamide 600 mg/m² 2-weekly for 8 weeks
Study: NCT00583713
Drug: BLI-800
Approvals — FDA: no, EMA: no, PMDA: no
Description: BLI-800 oral solution (two doses)
Study: NCT00796445
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: IM solution, a course of 13 injections administered over 27 months
Study: NCT04036292
Drug: OC-01 (varenicline) nasal spray
Normalized name: OC 8 Adult Acne
Approvals — FDA: no, EMA: no, PMDA: no
Description: OC-01 (varenicline) nasal spray
Study: NCT04036292
Drug: Placebo (vehicle) nasal spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (vehicle) nasal spray
Study: NCT00579384
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single dose of placebo on Day 1, and a second single dose of placebo on Day 3.
Study: NCT00628043
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subcutaneous administration of placebo once-weekly for 12 weeks
Study: NCT02049580
Drug: Cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Pre-transplantation Cyclophosphamide(Cy) 30 mg/kg/day will be administered as a 1-2 hour intravenous infusion with a high volume fluid flush on Days -5.~Cy will be dosed according to the recipient's ideal body weight (IBW), unless the patient weighs more than 125% of IBW, in which case the drug will be dosed according to the Adjusted IBW (AIBW)~Cyclophosphamide \[50 mg/kg/day IBW\] will be given on Day 3 post-transplant (between 60 and 72 hours after marrow infusion) and on Day 4 post-transplant (approximately 24 hours after Day 3 cyclophosphamide). Cyclophosphamide will be given as an IV infusion over 1-2 hours (depending on volume).
Study: NCT01299272
Drug: LY2216684
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01299272
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT04571164
Drug: Placebo,extended-release microspheres
Approvals — FDA: no, EMA: no, PMDA: no
Description: During the intervention,the initial does was 14mg,and then was incremented in weekly units,14mg each time,until the maximum does of 56mg set in this study was reached 4 weeks after titration,the optimal therapeutic does or the maximum tolerated does was entered into the dosing maintenance period.After entering the maintenance period,no does adjustment was performed,and the stable does was maintained for 24 weeks.
Study: NCT01491737
Drug: Aromatase Inhibitor
Normalized name: Aromatase inhibitor
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants will receive 1 mg anastrozole or 2.5 mg letrozole orally once daily.
Study: NCT01491737
Drug: Induction Chemotherapy
Normalized name: human sputum, Bordetella pertussis infected
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants receiving induction chemotherapy up to the first 18-24 weeks of the treatment period will receive a taxane (docetaxel every 3 weeks or paclitaxel weekly), administered in line with the respective pertuzumab and/or trastuzumab infusions at the investigator's discretion.
Study: NCT01888978
Drug: Modified FOLFOX-6
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01888978
Drug: FOLFIRI
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01888978
Drug: Tax-Iri
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT06700382
Drug: capecitabine
Normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: different methods of treatment for capecitabine
Study: NCT01281631
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: normal saline
Study: NCT00045942
Drug: PKC412
Approvals — FDA: no, EMA: no, PMDA: no
Description: PKC412 was supplied as soft gelatin capsules containing 25 mg PKC412.
Study: NCT00214721
Drug: Experimental Peritoneal Dialysis Solution
Normalized name: DEXTROSE/PERITONEAL DIALYSIS SOLUTION
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00303589
Drug: Standard care
Approvals — FDA: no, EMA: no, PMDA: no
Description: As prescribed
Study: NCT00303589
Drug: beta-lactam
Normalized name: Beta-lactam
Approvals — FDA: no, EMA: no, PMDA: no
Description: 750mg iv q8h
Study: NCT00303589
Drug: beta-lactam
Normalized name: Beta-lactam
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1500mg iv q8h
Study: NCT00422084
Drug: Coartem® (artemether lumefantrine)
Approvals — FDA: no, EMA: no, PMDA: no
Description: AL (20:120mg tablets) twice a day plus PA-placebo (once a day) for 3 consecutive days (Day 0, 1, and 2)
Study: NCT04406272
Drug: VB11
Normalized name: Valsartan and Bumetanide
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenously administered type of gene therapy that works by blocking the process of blood-vessel creation. Disrupting a cancer from growing blood vessels, might slow the growth of the cancer or shrink it.
Study: NCT01757418
Drug: Immune Globulin Intravenous (IVIG)
Normalized name: GLOBULIN,IMMUNE (IV)
Approvals — FDA: no, EMA: no, PMDA: no
Description: A single dose of intravenous immune globulin or saline placebo administered within 24 hours of hospital presentation. The maximum dose in Phase I was 800 mg/kg. The dose for Phase II is 400mg/kg.
Study: NCT01414920
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: TAK-875 and sitagliptin placebo-matching tablets, orally, once daily for up to 12 weeks.
Study: NCT00345332
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Injected
Study: NCT00001131
Drug: HAART
Normalized name: porcine heart preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Current HAART regimen to be continued for duration of therapy or until certain criteria specified by the study is met
Study: NCT00711516
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Matching Placebo dosed once-daily (50 mg/day (1 tablet) on Day 1; increased to 100 mg/day (2 tablets) starting on Day 2; increased to 150 mg/day (3 tablets) starting on Day 5; increased to 200 mg/day (4 tablets) starting on Day 8). Then continue 200 mg/day dosage through Day 14.
Study: NCT00021073
Drug: leucovorin calcium
Normalized name: Leucovorin Calcium
DrugBank: Leucovorin (DB00650)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Given IV
Study: NCT00021073
Drug: fluorouracil
Normalized name: Fluorouracil
DrugBank: Fluorouracil (DB00544)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Given IV
Study: NCT02353143
Drug: MEN1112
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous infusion of MEN1112 pro/Kg body weight dose will be administered for two 21-day cycles; MEN1112 dose is administered as' one shot infusion' (first group of patients) and as a dose to be infused in 3 days for the first two doses in Cycle 1 (second group of patients).~Two treatment cycles will be followed by a 4-week End of Treatment Period and a Follow-up period. The individual treatment/observation period is six months (except for female patients of childbearing potential that will undergo monthly pregnancy test until 6 months from the last study drug administration).
Study: NCT00662532
Drug: Minocycline HCl
Normalized name: minocycline HCl
DrugBank: Minocycline (DB01017)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 1mg microspheres for professional subgingival administration into periodontal pockets two times throughout the duration of the trial
Study: NCT00411580
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01328444
Drug: GSK 573719 +GW642444 125/25
Approvals — FDA: no, EMA: no, PMDA: no
Description: 125mcg/ 25mcg
Study: NCT01328444
Drug: GSK573719 + GW642444 62.5/25
Approvals — FDA: no, EMA: no, PMDA: no
Description: 62.5mcg/25mcg
Study: NCT01328444
Drug: GSK 573719 62.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: 62.5mcg
Study: NCT02092207
Drug: KL7016 900mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: oral administration, 150mg 3tab, bid
Study: NCT02092207
Drug: KL7016 600mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: oral administration, 150mg 3tab, bid
Study: NCT02092207
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: oral administration, 150mg 3tab, bid
Study: NCT01328444
Drug: GW642444 25
Approvals — FDA: no, EMA: no, PMDA: no
Description: 25mcg
Study: NCT03746288
Drug: CAN008
Approvals — FDA: no, EMA: no, PMDA: no
Description: CAN008 400 mg weekly over no less than 30 minutes via intravenous drip, followed by rRT that same day
Study: NCT02700334
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: one per day before breakfast during 12 weeks.
Study: NCT03340103
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo solution with unique excipients (Demineralised water, potassium sorbate, xanthan gum, citric acid)
Study: NCT01381562
Drug: Drug: GSK2251052
Approvals — FDA: no, EMA: no, PMDA: no
Description: Reconstituted, added to 250mL 0.9% NaCl solution and administered via IV infusion
Study: NCT00274092
Drug: Atrovent MDI (2 puffs of 20 mcg(q.i.d.) in patients
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01630278
Drug: Ibuprofen
Normalized name: Ibuprofen
DrugBank: Ibuprofen (DB01050)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Very premature infants with a large ductus, selected by an early echocardiogram, will receive ibuprofen before 12 hours of life
Study: NCT01630278
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Very premature infants with a large ductus, selected by an early echocardiogram, will receive placebo before 12 hours of life
Study: NCT01554696
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: oral
Study: NCT01554696
Drug: methotrexate
Normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: oral
Study: NCT02260570
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: A pill that contains no active ingredient
Study: NCT02730793
Drug: Nasal Placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (nasal saline twice per day)
Study: NCT01067339
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: placebo, by mouth, once daily for six months
Study: NCT03700515
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subjects receive weekly infusions of saline
Study: NCT03005184
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: intravenous medication
Study: NCT00658086
Drug: normal saline
Normalized name: Normal Saline Flush
Approvals — FDA: no, EMA: no, PMDA: no
Description: administered by nebulization once daily for 3 days
Study: NCT02001285
Drug: Remifentanil
Normalized name: Remifentanil
DrugBank: Remifentanil (DB00899)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: During intubation, remifentanil will be infused to prevent change arterial blood pressure and heart rate.
Study: NCT01829243
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02577393
Drug: mLDG
Approvals — FDA: no, EMA: no, PMDA: no
Description: mLDG (lidocaine 0.16mg/mL, dexamethasone 0.02mg/mL, and gentamycin 0.16mg/mL) dissolved in 0.9% saline solution was administered three times a day. Patients were given oral mLDG solution, and began medications as soon as grade 1 esophagitis occurred during radiation according to the RTOG criterion.
Study: NCT00769132
Drug: Comparator: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: matching placebo tablets for each of the interventions once daily for 7 days
Study: NCT00960232
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: placebo
Study: NCT00189410
Drug: Pegylated Liposomal Doxorubicin and Carboplatin
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT04140123
Drug: ZSP1601
Approvals — FDA: no, EMA: no, PMDA: no
Description: ZSP1601 tablets be taken orally for 28 days.
Study: NCT04140123
Drug: ZSP1601 Placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subjects will receive matching placebo of ZSP1601
Study: NCT00366093
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: placebo tablet
Study: NCT00949767
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: (Matching volume) - Oral Solution, Oral, once 14 days
Study: NCT01802918
Drug: GSK2838232
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bottled powder with 5, 10 and 20mg unit dose strength per single dose for re-constituted oral suspension given once daily
Study: NCT01802918
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Visually matching GSK2838232
Study: NCT01715597
Drug: ascorbic acid
Normalized name: Ascorbic Acid
DrugBank: Ascorbic acid (DB00126)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: ascorbic acid 2g in normal saline 500ml IV start 30min before the operation and infusion for 2 hour
Study: NCT01715597
Drug: Normal saline
Normalized name: Normal Saline Flush
Approvals — FDA: no, EMA: no, PMDA: no
Description: normal saline 500ml IV
Study: NCT00647829
Drug: valdecoxib
Normalized name: Valdecoxib
DrugBank: Valdecoxib (DB00580)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: valdecoxib 20 mg tablet by mouth twice daily (BID) for 2 doses over a 24-hour period
Study: NCT00647829
Drug: valdecoxib
Normalized name: Valdecoxib
DrugBank: Valdecoxib (DB00580)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: valdecoxib 40 mg tablet by mouth once daily (QD) for 2 doses over a 24-hour period
Study: NCT00647829
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: placebo tablet by mouth for 2 doses over a 24-hour period
Study: NCT03652805
Drug: IPL344
Approvals — FDA: no, EMA: no, PMDA: no
Description: The study is designed to determine the tolerability, safety and PK of IPL344 administered I.V. once a day for 28 days and to identify the maximum tolerated dose.~All patients enrolled will have a documented history of ALS disease prior to study enrollment.~Treatment will start with 1.7mg/kg with dose escalation by 0.5 mg/kg every 3-4 days and will increase to the maximum dose of 3.2mg/kg. Day 1 to Day 28 patients will be on active treatment.~After completion of 28 treatment days, participants who will choose to continue treatment (at the investigator's discretion), will be enrolled in a follow-up study. Participants that discontinue treatment after Day 28 will be followed up by a nurse phone call and return to the clinic for a final visit on Day 56 from the first dose.
Study: NCT04038840
Drug: [11C]UCB-J radiotracer
Approvals — FDA: no, EMA: no, PMDA: no
Description: I.V. bolus administration of up to 15 mCi (equivalent to 0.3 rems) in the antecubital vein
Study: NCT01997112
Drug: Placebo oral capsule
Normalized name: Placebo Oral Capsule
Approvals — FDA: no, EMA: no, PMDA: no